Opko Net Income Applicable To Common Shares from 2010 to 2024

OPK Stock  USD 1.58  0.03  1.94%   
Opko Health Net Loss yearly trend continues to be quite stable with very little volatility. Net Loss may rise above about -280.8 M this year. Net Loss is the net income that remains after preferred dividends have been deducted, available to common shareholders. View All Fundamentals
 
Net Loss  
First Reported
2000-03-31
Previous Quarter
-18.3 M
Current Value
-19.6 M
Quarterly Volatility
40.5 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Opko Health financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Opko Health's main balance sheet or income statement drivers, such as Depreciation And Amortization of 110.6 M, Interest Expense of 14.2 M or Total Revenue of 906.7 M, as well as many indicators such as Price To Sales Ratio of 1.25, Dividend Yield of 0.0011 or PTB Ratio of 0.78. Opko financial statements analysis is a perfect complement when working with Opko Health Valuation or Volatility modules.
  
Check out the analysis of Opko Health Correlation against competitors.
For more information on how to buy Opko Stock please use our How to buy in Opko Stock guide.

Latest Opko Health's Net Income Applicable To Common Shares Growth Pattern

Below is the plot of the Net Income Applicable To Common Shares of Opko Health over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Opko Health's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Opko Health's overall financial position and show how it may be relating to other accounts over time.
Net Income Applicable To Common Shares10 Years Trend
Slightly volatile
   Net Income Applicable To Common Shares   
       Timeline  

Opko Net Income Applicable To Common Shares Regression Statistics

Arithmetic Mean(136,454,000)
Geometric Mean66,308,351
Coefficient Of Variation(99.01)
Mean Deviation117,809,067
Median(114,827,000)
Standard Deviation135,105,925
Sample Variance18253.6T
Range359M
R-Value(0.58)
Mean Square Error13022.8T
R-Squared0.34
Significance0.02
Slope(17,551,350)
Total Sum of Squares255550.6T

Opko Net Income Applicable To Common Shares History

2024-280.8 M
2023-295.6 M
2022-328.4 M
2021-30.1 M
202030.6 M
2019-314.9 M
2018-138.5 M

About Opko Health Financial Statements

Opko Health investors utilize fundamental indicators, such as Net Income Applicable To Common Shares, to predict how Opko Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-295.6 M-280.8 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Opko Health is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Opko Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Opko Health Stock. Highlighted below are key reports to facilitate an investment decision about Opko Health Stock:
Check out the analysis of Opko Health Correlation against competitors.
For more information on how to buy Opko Stock please use our How to buy in Opko Stock guide.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opko Health. If investors know Opko will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opko Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.191
Earnings Share
(0.19)
Revenue Per Share
0.998
Quarterly Revenue Growth
(0.03)
Return On Assets
(0.09)
The market value of Opko Health is measured differently than its book value, which is the value of Opko that is recorded on the company's balance sheet. Investors also form their own opinion of Opko Health's value that differs from its market value or its book value, called intrinsic value, which is Opko Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opko Health's market value can be influenced by many factors that don't directly affect Opko Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opko Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Opko Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opko Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.